www.tnkase.com Review:

TNKase® Acute Myocardial Infarction Treatment - Learn more about single-bolus TNKase® (tenecteplase) acute myocardial infarction treatment and the 5-second TNKase® dosing and administration. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.

  • http://www.tnkase.com/tnkase-search-results TNKase® AMI Treatment Website Search Page - Search the TNKase® (tenecteplase) website for TNKase® dosing information, TNKase® treatment guidelines and information about AMI treatment. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.
  • http://www.tnkase.com/tnkase-dosing-and-administration TNKase® Dosing and Administration - Learn more about compliance with ACC/AHA recommendations for TNKase® (tenecteplase) dosing and administration for acute myocardial infarction treatment. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.
  • http://www.tnkase.com/tnkase-molecule-investigation TNKase® Molecule Investigation - Learn about TNKase® (tenecteplase) molecule, an advanced thrombolytic with properties relative to wild-type rtPA for acute myocardial infarction treatment. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.
  • http://www.tnkase.com/ami-treatment-clinical-trial-data Acute Myocardial Infarction Treatment Clinical Data - Find TNKase® (tenecteplase) AMI treatment clinical data, including ASSENT-2 clinical trial information, and the TNKase® clinical trial endpoints. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.
  • http://www.tnkase.com/tnkase-ami-treatment-resources TNKase® Acute Myocardial Infarction Treatment Resources - Discover clinical resources and publications on acute myocardial infarction treatment guidelines with TNKase® (tenecteplase), and the TNKase® dosing sheet. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.
  • http://www.tnkase.com/tnkase-replacement-program TNKase® Replacement Program - Learn more about Genentech's TNKase® (tenecteplase) replacement program for reconstituted TNKase® for patients that have let their TNKase® expire. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.
  • http://www.tnkase.com/tnkase-prescribing-information TNKase® Package Insert and TNKase® Prescribing Info - Learn more about TNKase® (tenecteplase) full package insert for acute myocardial infarction treatment from the TNKase® prescribing information. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.
  • http://www.tnkase.com/tnkase-dosing-card TNKase® Dosing Card for AMI Treatment - Register for a helpful TNKase® (tenecteplase) dosing card for acute myocardial infarction treatment with the simple weight-tiered TNKase® dosing. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.
  • http://www.tnkase.com/unsubscribe Unsubscribe from TNKase® Updates - Genentech respects your right to opt out of future communications about TNKase® (tenecteplase). Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.

    Country: 72.34.128.115, North America, US

    City: -118.244 California, United States

  • C. Williams - Use this EVERY night

    This is a must have in our home......we drink this every night prior to going to bed......calms our minds, helps with restless legs......we used this years ago....took a break..and are back on it. We won't be stopping again. Highly recommend.

  • BeemoChop - Amazing!

    I'm not even sure how many times we've bought this now but we have it on hand at all times. Best product we've tried for blemishes and treating/preventing razor burn. I especially love it for the bikini line which can be an annoying area when irritated. Works fast within hours and the difference is very noticeable. I also love their shave gel. Arrived quickly and as described. Will absolutely purchase again.

  • Patricia G. - I was impressed how fast they came and how easy they were to put on my jeep

    I was impressed how fast they came and how easy they were to put on my jeep! They do the job I wanted them to do... :)

  • dat603 - Helpful book during our trip to Germany

    This book was very helpful to us on our recent cycling trip in Germany. We received several hotel discounts when we showed them the book. The walking tour of Munich and historical places to visit proved helpful as well. We used the book to find wonderful dining establishments. The only drawback is we like to travel light and the book did add a bit of weight/volume but well worth it.

  • Mendy - Great deal for under 6 bucks

    My 2012: Doomsday & Countdown: Armageddon movie arrived on time and in good condition. I just bought a Blu-ray player and needed to buy a Blu-ray disc to try it out. I found this 2 disc set for under 6 bucks, why not I said. It was a great purchase. The movies were exciting to watch, not bad for $3 Blu-ray discs. I recommend these movies, the plots are interesting, not 'Armageddon' special effects but more than good enough, and for brand new Blu-ray discs for under 3 bucks makes this product well worth the money. A good product to add to your library of Blu-ray discs. I recommend this product. I give this a 5 star for value and entertaining purposes, not to mention it is Blu-ray.

  • R. M. Cook - Good razor for the price range

    The suckiest thing about electric razors is that it costs the same to replace the entire unit as it does to buy new blades. Obviously, there are far more expensive razors out there. But, if you are reading these reviews you are looking to buy something less expensive that does the job.

  • J. Oswald - Didn't last long

    Stopped working after about 6 months. Even factoring in the low price this is too expensive for the length of time it functioned. Maybe you will get better results because what I was doing was slow/low simmering bone broth for 48 hours outside while it's so hot in the summer. Perhaps that is asking too much of a little stove. I have a covered patio, weather wasn't the cause of failure. Using the lowest setting it stopped working in the middle of the cooking session. That was upsetting but I transitioned to the house oven which meant higher air conditioning bill. Looking for a better answer.